Home
Acrivon Therapeutics

Acrivon Therapeutics Market Share Analysis for May 2026

Developing best-in-class targeted therapies to improve the lives of patients.

Industry: N/A

Domainacrivon.com

Year Founded2018

Employees51 - 200

Annual Revenue--

Acrivon Therapeutics

Acrivon Therapeutics (including company regionals)

acrivon.com

See more website traffic and engagement information

Total visits to Acrivon Therapeutics's top domains

Understand Acrivon Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

acrivon.com8K

See more with Sales Intelligence

Avg. visit duration in Acrivon Therapeutics's top domains

Analyze Acrivon Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

acrivon.com00:00:12

See more with Sales Intelligence

Avg. pageviews on Acrivon Therapeutics's top domains

See how Acrivon Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

acrivon.com1.78

See more with Sales Intelligence

Acrivon Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Acrivon Therapeutics

These are the website technologies, by industry, used by Acrivon Therapeutics top domains

Advertising (4)

Google Adsense

Conversion & Analytics (3)

Google Analytics

Mobile (3)

Meta Viewport

Email Services (2)

G Suite

More Technologies

7

See all

News & Signals from Acrivon Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAcrivon Therapeutics, Inc attended event 7th Annual Oncology Innovation Summit on May 26th '26.WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) - Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat on Tuesday, May 26, 2026, at 9:00 a.m. ET at TD Cowen's 7th Annual Oncology Innovation Summit.

NewsAcrivon Therapeutics, Inc attends event 2026 AACR Annual Meeting.Acrivon Therapeutics to present pre-clinical AP3 Data at the 2026 AACR Annual Meeting revealing strong synergy of ACR-368 with ADC topo 1 inhibitor payloads and of both ACR-368 and ACR-2316 with immune checkpoint inhibitors.